4.37
price down icon0.46%   -0.02
 
loading
Schlusskurs vom Vortag:
$4.39
Offen:
$4.35
24-Stunden-Volumen:
13,428
Relative Volume:
0.04
Marktkapitalisierung:
$6.49M
Einnahmen:
$5.18M
Nettoeinkommen (Verlust:
$-7.79M
KGV:
-1.8517
EPS:
-2.36
Netto-Cashflow:
$-4.99M
1W Leistung:
-4.17%
1M Leistung:
-17.55%
6M Leistung:
-15.70%
1J Leistung:
-71.99%
1-Tages-Spanne:
Value
$4.31
$4.45
1-Wochen-Bereich:
Value
$4.26
$4.61
52-Wochen-Spanne:
Value
$3.54
$17.40

Evoke Pharma Inc Stock (EVOK) Company Profile

Name
Firmenname
Evoke Pharma Inc
Name
Telefon
858-345-1494
Name
Adresse
420 STEVENS AVENUE, SOLANA BEACH, CA
Name
Mitarbeiter
4
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
EVOK's Discussions on Twitter

Vergleichen Sie EVOK mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
EVOK
Evoke Pharma Inc
4.37 6.49M 5.18M -7.79M -4.99M -2.36
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
176.74 80.59B 9.15B 2.43B 2.31B 4.92
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.72 44.17B 14.26B 1.55B 0 0.3327
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
13.57 42.61B 30.27B 1.93B 3.45B 0.444
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.57 18.77B 16.77B -959.00M 1.37B -2.00
Drug Manufacturers - Specialty & Generic icon
VTRS
Viatris Inc
13.22 15.73B 15.05B -883.30M 1.89B 1.53

Evoke Pharma Inc Stock (EVOK) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2020-06-22 Hochstufung H.C. Wainwright Neutral → Buy
2019-03-05 Herabstufung H.C. Wainwright Buy → Neutral
2018-03-08 Bestätigt B. Riley FBR, Inc. Buy
2017-10-19 Fortgesetzt FBR & Co. Buy
2017-03-16 Bestätigt Rodman & Renshaw Buy
2017-01-30 Hochstufung Laidlaw Neutral → Buy
2017-01-05 Hochstufung Rodman & Renshaw Neutral → Buy
2016-12-23 Bestätigt Rodman & Renshaw Neutral
2016-07-19 Bestätigt FBR Capital Outperform
2016-07-19 Herabstufung Noble Financial Buy → Hold
2016-07-18 Herabstufung Rodman & Renshaw Buy → Neutral
2016-03-16 Eingeleitet Northland Capital Outperform
2016-03-14 Bestätigt Ascendiant Capital Markets Buy
2016-02-17 Fortgesetzt FBR Capital Outperform
2014-12-03 Bestätigt MLV & Co Buy
2014-11-07 Eingeleitet MLV & Co Buy
2014-04-22 Eingeleitet Laidlaw Buy
2013-11-19 Eingeleitet Aegis Capital Buy
Alle ansehen

Evoke Pharma Inc Aktie (EVOK) Neueste Nachrichten

pulisher
Nov 26, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve

Nov 26, 2024
pulisher
Nov 21, 2024

Mesenchymal Stem Cells (MSC) Market Set to Surpass USD 9.72 - GlobeNewswire

Nov 21, 2024
pulisher
Nov 20, 2024

Diabetic Gastroparesis Pipeline 2024: Clinical Trials - openPR

Nov 20, 2024
pulisher
Nov 16, 2024

EVOK (Evoke Pharma) Total Assets : $14.15 Mil (As of Sep. 2024) - GuruFocus.com

Nov 16, 2024
pulisher
Nov 15, 2024

Diabetic Gastroparesis Treatment Market: Global Size, Share, - openPR

Nov 15, 2024
pulisher
Nov 14, 2024

Altium Capital Management LP Increases Stake in Evoke Pharma Inc - GuruFocus.com

Nov 14, 2024
pulisher
Nov 13, 2024

Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com

Nov 13, 2024
pulisher
Nov 12, 2024

Nasal Drug Delivery Technology Market Breakthrough in Patient Care, Projected Market Growth to USD 7.8 Billion by 2031Market Research Intellect - The Malaysian Reserve

Nov 12, 2024
pulisher
Nov 12, 2024

By popular demand: SiGMA Europe launches fourth shed - GlobeNewswire Inc.

Nov 12, 2024
pulisher
Nov 12, 2024

Evoke Pharma (NASDAQ:EVOK) Coverage Initiated by Analysts at StockNews.com - Defense World

Nov 12, 2024
pulisher
Nov 10, 2024

Evoke Pharma Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 10, 2024
pulisher
Nov 08, 2024

Evoke Pharma earnings missed by $0.95, revenue fell short of estimates - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

(EVOK) Trading Advice - Stock Traders Daily

Nov 08, 2024
pulisher
Nov 08, 2024

BlackLine Announces the Planned Retirement of Chief Financial Officer and Names Successor - The Manila Times

Nov 08, 2024
pulisher
Nov 08, 2024

Evoke Pharma Reports Q3 2024 Financial Results - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Canopy Growth (CGC) Stock Surges 5.2% Amid Industry Movement - GuruFocus.com

Nov 07, 2024
pulisher
Nov 07, 2024

Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Nantahala Capital Management's Strategic Acquisition in Evoke Ph - GuruFocus.com

Nov 07, 2024
pulisher
Nov 06, 2024

Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve

Nov 06, 2024
pulisher
Nov 05, 2024

Ironwood Pharmaceuticals (IRWD) Sees Stock Surge Amid Positive A - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Is Abbott Laboratories (ABT) the Best Pharma Stock to Buy Right Now? - Yahoo Canada Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Evoke Pharma, Inc.'s (NASDAQ:EVOK) Shift From Loss To Profit - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com - Defense World

Nov 04, 2024
pulisher
Nov 03, 2024

Global Digestive Health Market Size, Share And Growth Analysis For 2024-2033 - EIN News

Nov 03, 2024
pulisher
Nov 01, 2024

Canopy Growth Corporation (CGC) Stock Price, News, Quote & History - Yahoo Finance

Nov 01, 2024
pulisher
Nov 01, 2024

Evoke Pharma (FRA:EV0) Enterprise Value : €1.02 Mil (As of Nov. 01, 2024) - GuruFocus.com

Nov 01, 2024
pulisher
Oct 30, 2024

Gastroparesis Treatment Market Top Trends and Growth Analysis: - openPR

Oct 30, 2024
pulisher
Oct 29, 2024

When Will Evoke Pharma, Inc. (NASDAQ:EVOK) Become Profitable? - Simply Wall St

Oct 29, 2024
pulisher
Oct 29, 2024

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 29, 2024
pulisher
Oct 29, 2024

Five things for pharma marketers to know for Tuesday morning - MM+M Online

Oct 29, 2024
pulisher
Oct 28, 2024

S&P 500 Moves Higher; Philips Shares Plunge After Q3 Earnings - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma holds Buy rating with $18 target from Laidlaw - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

EVOK Stock Earnings: Evoke Pharma Misses EPS, Misses Revenue for Q2 2024 - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma Shares Soar on Positive Data for Gimoti Nasal Treatment in Diabetic Gastroparesis - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

What made Evoke Pharma stock more than double on Monday? - Invezz

Oct 28, 2024
pulisher
Oct 28, 2024

Crude Oil Tumbles Over 5%; Autonomix Medical Shares Spike Higher - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma Shares Rise 70% on Gimoti Data in GLP-1 Users - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke stock rockets 90% on study of Gimoti in GLP-1 users (NASDAQ:EVOK) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma Stock Is Soaring Monday: What's Going On? - Benzinga

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma reports significant benefits of GIMOTI in DGP study - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma & EVERSANA Announce Statistically Significant - GlobeNewswire

Oct 28, 2024
pulisher
Oct 28, 2024

Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI® - StockTitan

Oct 28, 2024

Finanzdaten der Evoke Pharma Inc-Aktie (EVOK)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$90.27
price up icon 0.83%
$13.13
price up icon 0.00%
$86.59
price up icon 0.19%
$61.00
price up icon 0.41%
$126.59
price down icon 1.03%
$13.22
price up icon 1.07%
Kapitalisierung:     |  Volumen (24h):